Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice

Wu, Shu–Fen; Liao, Ching‐Len; Lin, Yi‐Ling; Yeh, Chia-Tsui; Chen, Li‐Kuang; Huang, Ya-Ling; Chou, Huei‐Chi; Huang, Jau‐Ling; Shaio, Men‐Fang; Sytwu, Huey‐Kang

doi:10.1016/s0264-410x(03)00310-4

Cited by 106 publications

(64 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, the protective effects conferred by tNS1 protein or DNA vaccine remain to be evaluated. The protection of NS1-DNA vaccine can be augmented, for example, by co-injection of plasmid encoding interleukin-12 as previously suggested [41] . This approach awaits further investigation.…”

Section: Discussionmentioning

confidence: 92%

C-Terminal Region of Dengue Virus Nonstructural Protein 1 Is Involved in Endothelial Cell Cross-Reactivity via Molecular Mimicry

Wan¹,

Lin²,

Chen³

et al. 2008

American J. of Infectious Diseases

View full text Add to dashboard Cite

Infection with dengue virus (DV) causes diseases ranging from self-limited dengue fever to life-threatening dengue hemorrhagic fever and dengue shock syndrome. Vascular leakage, thrombocytopenia and bleeding are the clinical manifestations associated with dengue hemorrhage. We previously showed that anti-DV nonstructural protein 1 (NS1) antibodies (Abs) cross-reacted with endothelial cells. The potential target proteins on endothelial cell surface recognized by anti-DV NS1 Abs showed sequence homology with the C-terminal amino acids (a.a.) 311-352 of DV NS1. In this study, the role of NS1 C-terminal region in dengue autoimmunity was investigated. We deleted the a.a. 277-352 of DV NS1 to prepare truncated NS1 (tNS1) and generated anti-DV tNS1 Abs in mice. The endothelial cell-binding activity of anti-DV tNS1 Abs was lower than that of anti-DV NS1 Abs. In addition, the endothelial cell-binding activity of anti-DV NS1 Abs was inhibited by preabsorption with DV NS1 but not with DV tNS1 proteins. The anti-P311 (a.a. 311-330) and anti-P331 (a.a. 331-350) titers of dengue patient sera were positively correlated with their endothelial cell-binding activity. Dengue patient sera showed lower binding activity to DV tNS1 than to DV NS1 proteins. The endothelial cell-binding activity of dengue patient sera was inhibited by preabsorption with P311 and P331. This study helps to understand the molecular mechanisms of autoimmunity mediated by anti-DV NS1 Abs and to provide the potential implications of tNS1 in dengue vaccine strategies.

show abstract

Section: Discussionmentioning

confidence: 92%

C-Terminal Region of Dengue Virus Nonstructural Protein 1 Is Involved in Endothelial Cell Cross-Reactivity via Molecular Mimicry

Wan¹,

Lin²,

Chen³

et al. 2008

American J. of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…12 Briefly, the Taiwanese local DEN-2 strain PL046, isolated from dengue fever patient, was used for the cloning of the NS1 gene. Virus propagation was carried out in C6/36 cells utilizing RPMI-1640 medium containing 5% fetal bovine serum (Sigma-Aldrich, St Louis, MO, USA).…”

Section: Materials and Methods Materialsmentioning

confidence: 99%

“…Animal immunization and challenge experiments were adapted from our previous report. 12 In brief, for challenge experiments, the BALB/c inbred strain mice was purchased from National Laboratory Animal Facility, National Science Council, Taipei, Taiwan, and were housed at the animal facility at the National Defense Medical Center under barrier conditions.…”

Section: Animal Study Immunization and Challenge Experiments In Micementioning

confidence: 99%

“…12 In brief, sera were collected by retroorbital sinus puncture from pD2NS1-immunized, pcDNAor PBS-treated mice at different times, beginning 1 week after final immunization, and analyzed for the presence of NS1-specific antibodies. For ELISA detection of anti-NS1 antibody, the 96-well microtiter plates were precoated with recombinant NS1 protein.…”

Section: Elisamentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine–loaded microspheres against dengue 2 virus

Huang¹,

Li²,

Hong³

et al. 2013

IJN

View full text Add to dashboard Cite

“…Animal immunization and challenge experiments were adapted from previous report. [31][32][33] In brief, for challenge experiments, the BALB/c inbred strain mice were purchased from National Laboratory Animal Facility, National Science Council, Taipei, Taiwan, Republic of China, and were housed at Animal Facility of National Defense Medical Center under barrier condition.…”

mentioning

confidence: 99%

Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague

Huang¹,

Li²,

Hong³

et al. 2014

IJN

View full text Add to dashboard Cite

Yersinia pestis F1 antigen-loaded poly( DL -lactide-co-glycolide)/polyethylene glycol (PEG) (PLGA/PEG) microspheres were produced using a water-in-oil-in-water emulsion/solvent extraction technique and assayed for their percent yield, entrapment efficiency, surface morphology, particle size, zeta potential, in vitro release properties, and in vivo animal protect efficacy. The Y. pestis F1 antigen-loaded microspheres (mean particle size 3.8 μm) exhibited a high loading capacity (4.5% w/w), yield (85.2%), and entrapment efficiency (38.1%), and presented a controlled in vitro release profile with a low initial burst (18.5%), then continued to release Y. pestis F1 antigen over 70 days. The distribution (%) of Y. pestis F1 on the microspheres surface, outer layer, and core was 3.1%, 28.9%, and 60.7%, respectively. A steady release rate was noticed to be 0.55 μg Y. pestis F1 antigen/mg microspheres/day of Y. pestis F1 antigen release maintained for 42 days. The cumulative release amount at the 1st, 28th, and 42nd days was 8.2, 26.7, and 31.0 μg Y. pestis F1 antigen/mg microspheres, respectively. The 100 times median lethal dose 50% (LD 50 ) of Y. pestis Yokohama-R strain by intraperitoneal injection challenge in mice test, in which mice received one dose of 40 μg F1 antigen content of PLGA/PEG microspheres, F1 antigen in Al(OH) 3 , and in comparison with F1 antigen in Al(OH) 3 vaccine in two doses, was evaluated after given by subcutaneous immunization of BALB/c mice. The study results show that the greatest survival was observed in the group of mice immunized with one dose of F1 antigen-loaded PLGA/PEG microspheres, and two doses of F1 antigen in Al(OH) 3 vaccine (100%). In vivo vaccination studies also demonstrated that F1 vaccines microspheres had a protective ability; its steady-state IgG immune protection in mice plasma dramatic increased from 2 weeks (18,764±3,124) to 7 weeks (126,468±19,176) after vaccination. These findings strongly suggest that F1-antigen loaded microspheres vaccine offer a new therapeutic strategy in optimizing the vaccine incorporation and delivery properties of these potential vaccine targeting carriers.

show abstract

Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice

Cited by 106 publications

References 46 publications

C-Terminal Region of Dengue Virus Nonstructural Protein 1 Is Involved in Endothelial Cell Cross-Reactivity via Molecular Mimicry

C-Terminal Region of Dengue Virus Nonstructural Protein 1 Is Involved in Endothelial Cell Cross-Reactivity via Molecular Mimicry

Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine–loaded microspheres against dengue 2 virus

Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague

Contact Info

Product

Resources

About

Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice

Cited by 106 publications

References 46 publications

C-Terminal Region of Dengue Virus Nonstructural Protein 1 Is Involved in Endothelial Cell Cross-Reactivity via Molecular Mimicry

C-Terminal Region of Dengue Virus Nonstructural Protein 1 Is Involved in Endothelial Cell Cross-Reactivity via Molecular Mimicry

Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine&ndash;loaded microspheres against dengue 2 virus

Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague

Contact Info

Product

Resources

About

Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine–loaded microspheres against dengue 2 virus